Navigation Links
Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
Date:10/6/2008

- Improved Pharmacokinetic Characteristics of Naltrexone SR Associated with

Better Tolerability in Clinical Trials -

PHOENIX, Oct. 6 /PRNewswire-FirstCall/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders, today presented data showing the investigational drug, Contrave(R) (naltrexone SR / bupropion SR), successfully achieved key objectives (lowered naltrexone Cmax, increased Tmax, comparable AUC) in two Phase 1 clinical trials. In addition, preliminary analysis of blinded data from nearly 4,000 patients participating in a series of four ongoing Phase 3 trials supports that the naltrexone SR formulation improvements are associated with tolerability advantages. Results from this series of investigations have been selected for presentation at The Obesity Society Annual Scientific Meeting.

"Contrave contains a sustained release formulation of naltrexone which we believe will improve tolerability, enhance patient compliance and improve weight loss outcomes in patients with obesity, a disorder which afflicts more than 75 million Americans," said Gary Tollefson, M.D., Ph.D., Orexigen President and CEO. "The Phase 3 formulation of naltrexone in an oral sustained release form may be a key factor in allowing more patients to achieve the potential benefits associated with greater weight loss."

About the Clinical Trials

The primary objective of the naltrexone sustained release (SR) development program was to improve tolerability by slowing the rate at which naltrexone dissolves, slowing its entry into the bloodstream (Tmax) and reducing the peak concentration it achieves in the blood (Cmax). A se
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... May 17, 2013 Research ... and outcomes research also   to   be presented ... SHPG ), the global specialty biopharmaceutical company, announces ... presentations at the American Psychiatric Association (APA) 166th Annual ... 18-22. The data being presented represent Shire,s ongoing commitment ...
(Date:5/17/2013)... , May 17, 2013 Fuse Science, Inc. (OTCQB: ... company that is developing new, patent-pending technologies poised to redefine ... that it will hold a business update teleconference and webcast ... nd , 2013 at 4:30 PM ET. ... will host the call and will be joined by ...
(Date:5/17/2013)... 17, 2013 Oramed Pharmaceuticals Inc. ... drug delivery systems, announced today that the United States ... Investigational New Drug application(IND) for ORMD-0801, its oral insulin ... the FDA clearance to proceed," stated Nadav ... is a major milestone for Oramed and we look ...
Breaking Medicine Technology:Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 2Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 3Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 4Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 5Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 6Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 7Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 8Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 9Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 10Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 3
... DailyMed(TM) Launches Innovative Solution to Medication Mismanagement ... ... medication,mismanagement continue to mount, emphasizing the urgent need for a,systematic change in ... At least 1.5 million Americans are sickened, injured or,killed each year by ...
... (N30), a,biopharmaceutical company focused on the discovery, development, ... today that it has successfully completed Phase 1,study ... develop N30-201 for,the treatment of reactive and obstructive ... are pleased to have begun and completed the ...
Cached Medicine Technology:More Than 1.5 Million Americans Sickened, Injured or Killed by Medication Errors Each Year; Seniors Most at Risk 2More Than 1.5 Million Americans Sickened, Injured or Killed by Medication Errors Each Year; Seniors Most at Risk 3More Than 1.5 Million Americans Sickened, Injured or Killed by Medication Errors Each Year; Seniors Most at Risk 4
(Date:5/18/2013)... (PRWEB) May 18, 2013 MOOSGO.COM published an ... , This book features a group of artists who share ... music, photographs, illustrations and paintings. Exclusively for iPad ... pieces including songs and videos that reflect the signature idiosyncrasy ... download at the Apple iBook Store and it includes ...
(Date:5/18/2013)... Assisted living and retirement communities ... and comfort of their residents. Systems Technologies is ... an effective and cost-efficient solution – VisionLink Wireless ... turnkey communications solution that helps nurses provide the ... and privacy. , The VisionLink nurse ...
(Date:5/18/2013)... Reporter , , FRIDAY, May 17 (HealthDay News) -- It comes ... new research shows that college women are more likely to ... are college men. Much of this difference is ... a weekly basis is much lower for women than it ... men. But, there,s good reason for that difference. Women don,t ...
(Date:5/18/2013)... York, New York (PRWEB) May 18, 2013 ... to mount in courts throughout the country, Bernstein Liebhard ... metal-on-metal hip replacement patients often suffer tissue damage before ... the study, which according to Science Daily will appear ... metal-on-metal hip replacement recipients underwent MRI screens of their ...
(Date:5/18/2013)... 6Webs.com is the leader in home ... comprehensive comparisons make 6Webs.com the useful resource consumers prefer ... recently finished conducting their assessments of the leading wireless ... 6Webs.com reports, "There has been an increase interest in ... use, expandability and mobility. Combine these features with the ...
Breaking Medicine News(10 mins):Health News:New Art Book for iPad: Tango Art 2Health News:VisionLink Nurse Call System's New Features Serve the Unique Needs of Retirement Communities 2Health News:VisionLink Nurse Call System's New Features Serve the Unique Needs of Retirement Communities 3Health News:College Women More Prone to Problem Drinking Than Men: Study 2Health News:College Women More Prone to Problem Drinking Than Men: Study 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 2Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 4Health News:Best Wireless Home Security System Companies Released by 6Webs.com 2
... flu in ducks on Indonesia's resort island of Bali, health ... of bird flu// . The birds had been smuggled to ... Putra, senior government veterinarian. ,More than 24 bird ... most populous nation. In response to the above situation, import ...
... Bolivar University in Caracas found that Lactobacillus casei (L ... flatulence capacity// and increased the nutritional value. Beans are ... the developing countries. ,Marisela Granito led the ... beans but not compromising on the nutritional value. The ...
... men are more aware of potential rivals for love when ... that men// become more jealous and wary of dominant males ... ,The Evolution and Human Behaviour study by the ... were vary wary of the dominant looking men who attract ...
... has been launched by Watson Pharmaceuticals, Inc. , ... agreement with Bristol-Myers Squibb Company. Shipments of pravastatin ... the 10, 20 and 40 mg strengths. ... Corona, CA. It is a leading specialty pharmaceutical ...
... they have found a new way to boost the immune ... at risk for developing various infections since their immune systems ... published in the online edition of the journal Blood on ... Division of Infectious Diseases show that the newborn immune system ...
... researchers suggests that injuries related to wearing glasses account ... of protective eyewear while engaging in activities that increase ... ,The researchers estimated that, in 2002 and 2003, ... treatment for injuries related to wearing glasses. More than ...
Cached Medicine News:Health News:Jealousy In Men Peaks When Partners Are Most Fertile 2Health News:Enhancing Infants Immune System 2Health News:Enhancing Infants Immune System 3Health News:Watch Out! Eye Glass Related Injuries On The Rise 2Health News:Watch Out! Eye Glass Related Injuries On The Rise 3
... material have been applied to a new Pe.R.I. ... ultra-low profile combine to provide a complete set ... ,This complete set of periarticular plates consists of: ... Composite Plate , Spider Plate ...
Standard Trephine...
X-Hair Trephines...
Corneal Marking Pen - Sterile. 10 pieces/box...
Medicine Products: